The Diagnostics Platform develops cutting-edge technologies for rapid, sensitive, and cost-effective detection of diseases and contaminants. Leveraging advances in nanotechnology, biosensors, and molecular biology, we aim to enable early diagnosis and real-time monitoring of health and environmental conditions.

Our approach integrates microfluidics, lab-on-a-chip devices, and AI-driven signal analysis to enhance diagnostic speed, accuracy, and portability. By designing user-friendly and field-deployable systems, the platform seeks to bridge the gap between laboratory innovation and practical healthcare solutions.

Simon Corrie research interest is focused on developing nano-particle-based molecular sensors and contrast agents for monitoring biological molecules in real biological environments. The Nano-sensor Engineering Lab works on the design, synthesis, characterization and testing of both synthetic nano-particles polymers, and biomolecules (e.g. peptides, proteins, antibodies) to detect and report the concentration of important disease biomarkers, in a real-time or rapid manner. This requires an interdisciplinary approach, combining aspects of materials science, chemistry, and molecular biology to create the materials and then collaborate with Australian and international colleagues to test the materials in pre-clinical animal models or human samples, with the ultimate aim of translation into human trials.

Prof. Gil Garnier

• Portable testing – developing handheld and paper-based devices for rapid, low-cost, and accurate blood typing.
• Innovative biomaterials – using cellulose gels and capillary flow models to create alternative diagnostic platforms.
• Transfusion safety – advancing methods to assess red cell longevity and improve pre-transfusion testing accuracy.